Description: Playing a key role in developing life-saving cancer immunotherapies
cancer (3356) clinical trials (400) cll (21) tnf (10) chronic lymphocytic leukemia (7) bob coates (2) memgen (1) isf35 (1) active immune therapy (1) robert coates (1)
Findings point to new therapeutic strategy to maximize dendritic cell-induced T-cell activation with potential to benefit patients as a single agent and in combination with immune checkpoint inhibitors.
Oncolytic virus expressing CD40 ligand and IFNβ reduces tumor size, activates immune cells in phase 1 trial
Clinical Trials Update Memgen is slated to begin clinical trials of MEM-288 in Spring 2022. Details coming soon.